In order to ensure that you continue to receive information that is of interest from PharmaVentures help us by subscribing. Thank you for your co-operation. Special 15% reduced rate for multiple report orders PharmaVentures Intelligence is now offering a special reduced rate on all orders for 2 or more copies of our leading reports. Our business publications are written to ensure companies in the pharmaceutical and biotech sector generate optimum results from all their deal making activities. Review our report titles and order your copies before the 31st May 2005 to take advantage of the 15% discount. Market News and Trends In April, Vectura and Arakis entered into an agreement with Novartis relating to a product in development for COPD. The product, AD 237, is currently in Phase II development. The deal is initially worth US$15 M to Vectura and Arakis. Read more... Featured Article Strategies for Intracellular Drug Delivery Many different technologies have been devised to deliver drugs intracellularly. Jonathan Kearsey (Diatos SA) reviews some of the novel technologies that have been developed, which are aimed to overcome the highly selective barrier of the cell membrane. In particular, "last mile" technologies that attempt to deliver drugs to the cytoplasm or the nucleus are discussed. Read more... Company Profiles Camurus, Owen Mumford, Soliqs, Sontra Medical Drug Delivery Opportunities Featured Opportunity Analgesic patches Administrative route - Topical Indication - Pain Licence code LO-0398-16 To profile your own opportunities, request a password or alternatively view all our drug delivery opportunities online. New Autumn/Winter 2005 Drug Delivery Report Find out about profiling your company in the next edition of the Drug Delivery Report. Alternatively make sure you receive your copy by applying online.
Drug Delivery E-News is produced by PharmaVentures Intelligence, part of PharmaVentures - a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with clients to drive greater value from their deals. If you do not wish to receive E-News in future, please email ddcr@pharmamail.biz with the words UNSUBSCRIBE as the subject. If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddcr@pharmamail.biz with REMOVE as the subject. For more details contact Mel Hemamda, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@ddcr.com www.ddcr.com